Trial Profile
A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Enasidenib (Primary) ; Azacitidine; Cytarabine; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms IDHENTIFY
- Sponsors Celgene Corporation
- 06 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Mar 2024.
- 06 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Mar 2024.
- 19 Jan 2024 This trial has been completed in Denmark.